STOCK TITAN

SCYNEXIS (SCYX) SEC Filings

SCYX NASDAQ

SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.

SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.

Rhea-AI Summary

For SCYNEXIS, Inc. (SCYX), Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl each report beneficial ownership of 4,076,068 shares, or 9.99%, with shared voting and dispositive power over that amount. The reported ownership is tied to September 30, 2026.

The reporting persons say 55,187 shares underlying warrants are beneficially owned, subject to a Beneficial Ownership Cap that restricts warrant exercises that would put holders and affiliates above 9.99%. The percentage calculation uses 10,004,796 shares, comprising 9,949,609 shares outstanding reported in SCYNEXIS’s Form 10-Q filed August 10, 2026, plus the 55,187 warrant shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
ownership
-
Rhea-AI Summary

Scynexis, Inc. (SCYX) is the issuer in an amended ownership report by Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Private Master Fund I LP and Michael Gregory. Each reporting person lists beneficial ownership of 1,087,235 shares, or 9.9% of the class, with shared voting and dispositive power and zero sole voting or dispositive power. The shares are directly owned by advisory clients of Avidity Partners Management LP; only Avidity Private Master Fund I LP may be deemed to beneficially own more than 5% of the class. Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.35%
Tags
ownership
-
Rhea-AI Summary

SCYNEXIS, Inc. has filed a replacement shelf registration covering up to an aggregate offering amount of $200,000,000 in common stock, preferred stock, debt securities and warrants, individually or in combination, for offerings after effectiveness. All securities registered under the expiring shelf remained unsold as of the new statement’s filing, and SCYNEXIS says no additional securities are being registered. The old shelf is due to expire November 27, 2026; SCYNEXIS may continue issuing and selling securities covered by it until the earlier of the new statement’s effectiveness or 180 days after that date.

Unless an offering-specific supplement states otherwise, net proceeds, if any, are intended for working capital and general corporate purposes; pending use, they would be temporarily invested in short-term, interest-bearing instruments. SCYNEXIS reports a public float of approximately $52.5 million as of November 3, 2026, and states that the value of a public primary offering may not exceed one-third of public float in any 12-month period unless public float subsequently rises to $75.0 million or more.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.06%
Tags
registration
Rhea-AI Summary

SCYNEXIS, Inc. reported its third-quarter and nine-month 2026 results, including a $22.36 million net loss for the nine months ended September 30, 2026. Nine-month license revenue was $235,000, versus $1.955 million a year earlier; research and development expense was $22.441 million, including an $8.0 million acquired in-process research and development charge for SCY-770. Operating cash use was $30.452 million, and cash, cash equivalents and investments totaled $63.2 million at September 30, 2026. The company expects to need substantial additional funding as development continues.

A BARDA contract provides approximately $18.5 million in its initial base period; potential total funding is up to $213.9 million, subject to BARDA exercising up to six options, which could extend the contract for up to ten years. The March 2026 private placement generated $40.0 million in gross proceeds and $36.9 million in net proceeds; cash exercise of the warrants could provide up to $52.2 million in additional gross proceeds.

SCYNEXIS completed Phase 1 studies of SCY-770 and intravenous SCY-247. It anticipates starting the SCY-770 ADPKD Phase 2 study in the fourth quarter of 2026 and an interim analysis in the fourth quarter of 2027; it anticipates a SCY-247 Phase 2 study in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.06%
Tags
quarterly report
-
Rhea-AI Summary

SCYNEXIS, Inc. entered into an Award/Contract with BARDA to support development of SCY-247, its second-generation fungerp antifungal candidate. BARDA’s potential total non-dilutive funding is up to $214 million. The initial base period commences in September 2026 and provides approximately $18.5 million to advance oral and intravenous SCY-247 into a Phase 2 study in patients with invasive candidiasis. The remaining potential award is subject to BARDA exercising up to six options, which could extend the contract for up to ten years.

If all options are exercised, the contract could fund SCY-247 development through New Drug Application submissions for treatment of invasive candidiasis and prevention of invasive fungal infections in high-risk patients. It is a cost-share arrangement: BARDA supports eligible direct and general and administrative expenses, while SCYNEXIS expects to fund its share of near-term program costs within its existing operating plan. The company said its previously communicated SCY-770 development plans and projected cash runway into 2029 remain unchanged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
current report
-
Rhea-AI Summary

SCYNEXIS INC (SCYX) reported that director Steven Keith Burke received new equity awards on September 18, 2026. He was granted 5,750 restricted stock units, each convertible into one share of common stock as they vest, and 5,750 stock options to buy common shares at an exercise price of $4.46 per share, expiring on September 18, 2036. One third of the RSUs will vest each year on the grant-date anniversary starting September 18, 2027, and the options vest one third on the first anniversary of the grant date, with the remaining two thirds vesting in equal monthly installments over the following 24 months, in each case contingent on his continued service. Following these awards he holds 5,750 common shares directly, plus 5,750 stock options, and no Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
insider
Rhea-AI Summary

SCYNEXIS INC (SCYX) disclosed that Steven Keith Burke has become a reporting person by filing an initial statement of beneficial ownership of securities as a director. The filing does not report any current holdings of SCYNEXIS securities or any recent transactions in the company’s securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
insider
-
Rhea-AI Summary

SCYNEXIS, Inc. (SCYX) announced that its Board appointed Steven K. Burke, M.D. as a director effective September 18, 2026, with his term running until the 2027 annual meeting, and named him to the Board’s Nominating and Corporate Governance Committee.

As a non-employee director, Dr. Burke will receive annual cash retainers and initial equity awards, including stock options and restricted stock units with multi‑year vesting schedules. The company highlights his more than 30 years of biopharmaceutical experience and nephrology-focused drug development background to support the advancement of SCY-770, its orphan-designated AMPK activator being developed for Autosomal Dominant Polycystic Kidney Disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.45%
Tags
current report
-
Rhea-AI Summary

SCYNEXIS INC (SCYX) reported that its Chief Financial Officer, Sanjay Subramanian, received a grant of stock options on September 9, 2026 to purchase 100,000 shares of common stock at an exercise price of $4.91 per share. These options expire on September 8, 2036 and vest 25% after one year, with the remainder vesting in equal monthly installments over the following 36 months, contingent on continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
insider
Rhea-AI Summary

SCYNEXIS INC (SCYX) reported that Sanjay Subramanian, the company’s Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. The filing does not list any reportable transactions or equity holdings in SCYNEXIS common stock or derivatives as of the reporting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
insider

FAQ

How many SCYNEXIS (SCYX) SEC filings are available on StockTitan?

StockTitan tracks 63 SEC filings for SCYNEXIS (SCYX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for SCYNEXIS (SCYX)?

The most recent SEC filing for SCYNEXIS (SCYX) was filed on November 16, 2026.